Last reviewed · How we verify

Bupivicaine + epinephrine

Rush University Medical Center · FDA-approved active Small molecule

Bupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption.

Bupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption. Used for Local and regional anesthesia for surgical, dental, and pain management procedures.

At a glance

Generic nameBupivicaine + epinephrine
SponsorRush University Medical Center
Drug classLocal anesthetic with vasopressor
TargetVoltage-gated sodium channels; alpha and beta-adrenergic receptors
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx into nerve fibers, preventing depolarization and conduction of nerve impulses. Epinephrine, an alpha and beta-adrenergic agonist, causes vasoconstriction of local blood vessels, which slows the systemic absorption of bupivacaine, extends its duration of action, and reduces the risk of systemic toxicity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: